Gene expression profiling with microarray and SAGE identifies PLUNC as a marker for hepatoid adenocarcinoma of the stomach

Sentani, Kazuhiro; Oue, Naohide; Sakamoto, Naoya; Arihiro, Koji; Aoyagi, Kazuhiro; Sasaki, Hiroki; Yasui, Wataru

doi:10.1038/modpathol.3801050

Cited by 50 publications

(30 citation statements)

References 30 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GHAC is frequently positive for AFP (91%), cytokeratin (CK)18/CK19 (100%), CK20 (25%), pancytokeratin (AE1/AE3) (92.3%) and α1-antitrypsin (91%) (13), and glypican-3 has been reported to be useful in the differential diagnosis between GHAC and HCC (1). In addition to these markers, palate, lung and nasal epithelium carcinoma-associated protein represents a promising marker in distinguishing HAC from HCC, since it is detected in liver metastases of GHAC, but not in HCC (14). However, none of these markers are sensitive or specific enough.…”

Section: Discussionmentioning

confidence: 99%

Hepatoid adenocarcinoma of the stomach: Nine case reports and treatment outcomes

Cheng

Jiang

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. Hepatoid adenocarcinoma (HAC), an extrahepatic tumor, has notable morphological similarities to hepatocellular carcinoma, which has been reported in gastrointestinal tract organs, including the rectum, gallbladder, lung, ovary and urinary bladder. HAC of the stomach (GHAC) is a rare variant of gastric cancer, characterized by aggressive behavior and extremely poor prognosis. Correct diagnosis depends on clinicopathological and immunohistochemical studies. In the present study, we reported nine cases of GHAC who were treated in the First Affiliated

show abstract

Section: Discussionmentioning

confidence: 99%

Hepatoid adenocarcinoma of the stomach: Nine case reports and treatment outcomes

Cheng

Jiang

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…We previously performed several large-scale gene expression studies using array-based hybridization [7] and serial analysis of gene expression [8,9], and identified a number of genes, including REG4 (which encodes regenerating islet-derived protein 4) [10,11] OLFM4 (which encodes olfactomedin 4) [12], BPIFA1, also known as PLUNC (which encodes palate, lung, and nasal epithelium carcinoma associated protein) [13], and GJB6 (which encodes connexin 30) [14]. Our recent study of Escherichia coli ampicillin secretion trap (CAST) analysis on GC cell lines and cancer tissues identified several candidate genes.…”

Section: Introductionmentioning

confidence: 99%

Fukutin, identified by the Escherichia coli ampicillin secretion trap (CAST) method, participates in tumor progression in gastric cancer

Sentani

Mukai

et al. 2015

Gastric Cancer

Self Cite

View full text Add to dashboard Cite

Background Gastric cancer (GC) is the fifth commonest malignancy worldwide and still one of the leading causes of cancer-related death. The aim of this study was to identify a novel prognostic marker or therapeutic target for GC. Methods We analyzed candidate genes from our previous Escherichia coli ampicillin secretion trap (CAST) libraries in detail, and focused on the FKTN gene because it was overexpressed in both GC cell line CAST libraries, MKN-1 and MKN-45. Results Quantitative reverse transcriptase PCR analysis of FKTN revealed that FKTN messenger RNA was overexpressed in nine of 28 (32.1 %) GC tissue samples compared with nonneoplastic gastric mucosa. Immunostaining of fukutin showed that 297 of 695 cases (42.7 %) were positive for fukutin. Fukutin-positive GC cases were significantly associated with differentiated histological features, and advanced T grade and N grade. In addition, fukutin expression was observed more frequently in the intestinal phenotype (51 %) of GC than in other phenotypes (37 %) when defined by the expression patterns of mucin 5AC, mucin 6, mucin 2, and CD10. FKTN small interfering RNA treatment decreased GC cell proliferation. Conclusions These results indicate that the expression of fukutin may be a key regulator for progression of GC with the intestinal mucin phenotype.

show abstract

“…Immunohistochemical analysis may exhibit positive staining for epithelial membrane antigen and CEA, which may aid in the exclusion of gastric metastasis of HCC (4,8,10,11). New molecular markers, including palate, lung, and nasal epithelium clone protein and GATA4, may allow the differentiation of gastric hepatoid adenocarcinoma, HCC and CGC (15,16).…”

Section: A B C Dmentioning

confidence: 99%

Hepatoid adenocarcinoma of the stomach: A case report and review of the literature

et al. 2015

View full text Add to dashboard Cite

Abstract. Hepatoid adenocarcinoma is a rare tumor, associated with an extremely poor prognosis. In the present report, a 72-year-old female presented to Huashan Hospital (Shanghai, China) with upper abdominal discomfort and, following endoscopy, an ulcerated lesion was observed in the stomach. A computed tomography scan revealed a mass in the antrum of the stomach and the α-fetoprotein level was normal. Sections of the mass exhibited malignant cells arranged in a solid to trabecular pattern; the cells were polygonal shaped with well-defined cytoplasmic borders. Immunohistochemical analysis was performed and the cells were positive for Hep1, CK, CK8, CK18 and P53. The histological features together with the immunohistochemical findings were diagnostic of a hepatoid adenocarcinoma of the stomach. Immunohistochemical studies may aid in the identification of the characteristic features and prevent the misdiagnosis of this tumor. IntroductionHepatoid adenocarcinoma of the stomach (HAS) is a particular type of extrahepatic adenocarcinoma, presenting with morphological characteristics identical to those of hepatocellular carcinoma (HCC). A case of α-fetoprotein-producing gastric adenocarcinoma was reported by Ishikura et al (1) in 1985. The authors suggested the name of HAS due to the ability of the tumor cells to produce α-fetoprotein (AFP), which is characteristic of hepatoid adenocarcinoma cells (1). HAS is reported to occur with more frequent lymph node and liver metastasis and exhibits a poorer prognosis than common gastric cancer (CGC) (2). HAS is rare (with a worldwide incidence of 0.3-1%) of all kinds of gastric cancer (2-4), the sypmtoms are similar to those of normal gastric cancer (abdominal discomfort, fullness of anorexia, epigastric pain, voimiting and weight loss), surgery is the usual treatment option (4-7). The literature review presented in this study was conducted to contribute towards the improvement of the diagnosis and treatment of HAS (3). We report a case of a 72-year-old female patient who sufferd upper abdominal discomfort. Endoscopical and radiological examination revealed a neoplasm in the stomach, however serum α-fetoprotein levels were normal. Written informed consent was obtained from the patient's family. Case reportCase presentation. A 72-year-old Chinese female presented to Huashan Hospital (Shanghai, China) complaining of upper abdominal discomfort for the previous two months. The patient was admitted to the General Surgery Department of Huashan Hospital on October 8th, 2011. The results of the physical examinations were unremarkable. The past medical history revealed nothing significant; the patient had not previously undergone any surgery and there was no family history of cancer. The laboratory investigation revealed normal blood levels following routine tests, and liver and kidney function were normal. The white blood cell count was 6.8x10 9 /l (normal range, 4.5-11x10 9 /l), the hematocrit level was 120 g/l (normal range, 110-150 g/l), the red blood cell count was 3.93x10 12 /l (...

show abstract

Gene expression profiling with microarray and SAGE identifies PLUNC as a marker for hepatoid adenocarcinoma of the stomach

Cited by 50 publications

References 30 publications

Hepatoid adenocarcinoma of the stomach: Nine case reports and treatment outcomes

Hepatoid adenocarcinoma of the stomach: Nine case reports and treatment outcomes

Fukutin, identified by the Escherichia coli ampicillin secretion trap (CAST) method, participates in tumor progression in gastric cancer

Hepatoid adenocarcinoma of the stomach: A case report and review of the literature

Contact Info

Product

Resources

About